Federal Register of Legislation - Australian Government

Primary content

PB 10 of 2020 Determinations/Health as made
This instrument amends the National Health (Price and Special Patient Contribution) Determination 2010 (PB 109 of 2010) by adding a new brand premium to nine brands of nine pharmaceutical items and increasing the brand premium for several brands of pharmaceutical items. It also reinstates one brand premium to one pharmaceutical item in addition to removing one brand of one pharmaceutical item that will no longer be PBS listed on 1 February 2020.
Administered by: Health
Registered 30 Jan 2020
Tabling HistoryDate
Tabled HR04-Feb-2020
Tabled Senate04-Feb-2020
Date of repeal 15 May 2020
Repealed by Division 1 of Part 3 of Chapter 3 of the Legislation Act 2003

PB 10 of 2020

 

National Health (Price and Special Patient Contribution) Amendment Determination 2020 (No. 1)

 

National Health Act 1953

___________________________________________________________________________

 

I, THEA DANIEL, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this Determination under section 85B of the National Health Act 1953.

 

Dated 29 January 2020

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

THEA DANIEL

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

 


_________________________________________________________________________

1          Name of Instrument

(1)          This Instrument is the National Health (Price and Special Patient Contribution) Amendment Determination 2020 (No. 1).

(2)          This Instrument may also be cited as PB 10 of 2020.

2          Commencement

This Instrument commences on 1 February 2020.

3          Amendment of National Health (Price and Special Patient Contribution) Determination 2010 (PB 109 of 2010)

Schedule 1 amends the National Health (Price and Special Patient Contribution) Determination 2010 (PB 109 of 2010).

 


Schedule 1     Amendments

[1]   Schedule 1, entry for Cefaclor in the form Powder for oral suspension 125 mg (as monohydrate) per 5 mL, 100 mL

omit from the column headed “Claimed Price”:                       7.85        substitute:                10.55

[2]   Schedule 1, entry for Cefaclor in the form Powder for oral suspension 250 mg (as monohydrate) per 5 mL, 75 mL

omit from the column headed “Claimed Price”:                       8.25        substitute:                10.75

[3]   Schedule 1, entry for Cefaclor in the form Tablet (sustained release) 375 mg (as monohydrate)

omit from the column headed “Claimed Price”:                       9.32        substitute:                10.94

[4]   Schedule 1, after entry for Diclofenac in the form Tablet (enteric coated) containing diclofenac sodium 50 mg

Insert:

Dicloxacillin

Capsule 250 mg (as sodium)

Oral

Distaph 250

24

4.30

6.11

 

Capsule 500 mg (as sodium)

Oral

Distaph 500

24

7.53

9.35

[5]   Schedule 1, after entry for Dorzolamide with timolol in the form Eye drops containing dorzolamide 20 mg (as hydrochloride) with timolol 5 mg (as maleate) per mL, 5 mL

Insert:

Dosulepin

Capsule containing dosulepin hydrochloride 25 mg

Oral

Dothep 25

50

2.39

4.20

 

Tablet containing dosulepin hydrochloride 75 mg

Oral

Dothep 75

30

2.39

4.20

[6]   Schedule 1, after entry for Hydrocortisone in the form Ointment containing hydrocortisone acetate 10 mg per g, 50 g

Insert:

 

Tablet 4 mg

Oral

Hysone 4

50

13.45

16.24

 

Tablet 20 mg

Oral

Hysone 20

60

19.20

21.99

Hydromorphone

Injection containing hydromorphone hydrochloride 2 mg in 1 mL

Injection

Dilaudid

5

10.07

13.79

 

Injection containing hydromorphone hydrochloride 10 mg in 1 mL

Injection

Dilaudid-HP

5

13.43

17.15

[7]   Schedule 1, entry for Levonorgestrel wih Ethinylestradiol in the form Pack containing 21 tablets 150 micrograms‑30 micrograms and 7 inert tablets [Brand: Levlen ED]

omit from the column headed “Claimed Price”:                       8.94        substitute:                9.37

[8]   Schedule 1, after entry for Metformin in the form Tablet (extended release) containing metformin hydrochloride 1 g

Insert:

Methyldopa

Tablet 250 mg (as sesquihydrate)

Oral

Aldomet

100

8.18

11.05

[9]   Schedule 1, after entry for Oxazepam in the form Tablet 30 mg

Insert:

Oxycodone

Tablet containing oxycodone hydrochloride 5 mg

Oral

Endone

20

1.81

3.67

[10] Schedule 1, entry for Ranitidine

Omit:

 

Tablet, effervescent, 150 mg (as hydrochloride)

Oral

Zantac

30

1.81

2.35

[11] Schedule 1, entry for Telmisartan in the form Tablet 40 mg

omit from the column headed “Claimed Price”:                       5.15        substitute:                5.83

[12] Schedule 1, entry for Telmisartan in the form Tablet 80 mg

omit from the column headed “Claimed Price”:                       8.28        substitute:                8.97

[13] Schedule 1, entry for Telmisartan with amlodipine in the form Tablet 40 mg‑5 mg (as besilate)

omit from the column headed “Claimed Price”:                       5.92        substitute:                6.60

[14] Schedule 1, entry for Telmisartan with amlodipine in the form Tablet 40 mg‑10 mg (as besilate)

omit from the column headed “Claimed Price”:                       6.52        substitute:                7.21

[15] Schedule 1, entry for Telmisartan with amlodipine in the form Tablet 80 mg‑5 mg (as besilate)

omit from the column headed “Claimed Price”:                       9.05        substitute:                9.74

[16] Schedule 1, entry for Telmisartan with amlodipine in the form Tablet 80 mg‑10 mg (as besilate)

omit from the column headed “Claimed Price”:                       9.65        substitute:                10.33

[17] Schedule 1, entry for Telmisartan with hydrochlorothiazide in the form Tablet 40 mg‑12.5 mg

omit from the column headed “Claimed Price”:                       5.62        substitute:                6.31

[18] Schedule 1, entry for Telmisartan with hydrochlorothiazide in the form Tablet 80 mg‑12.5 mg

omit from the column headed “Claimed Price”:                       8.79        substitute:                9.48

[19] Schedule 1, entry for Telmisartan with hydrochlorothiazide in the form Tablet 80 mg‑25 mg

omit from the column headed “Claimed Price”:                       9.26        substitute:                9.94